Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
about
Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculationResection and reconstruction of pelvic and extremity soft tissue sarcomas with major vascular involvement: Current conceptsTrial Watch-Immunostimulation with cytokines in cancer therapyTreatment of Adult Soft Tissue Sarcomas: An OverviewAttenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 functionCurrent and future technology for minimally invasive ablation of renal cell carcinomaIn vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer.Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusionsIsolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityLack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusionOne hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Factors Influencing Prognosis After Initial Inadequate Excision (IIE) for Soft Tissue Sarcoma.Lower limb function and quality of life after ILP for soft-tissue sarcoma.Preclinical experimental therapeutic approaches in soft tissue sarcoma.Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?Trial watch: Immunostimulatory cytokines in cancer therapy.Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose mattersIsolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials.Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicineThe pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis.Manipulation of the tumour-associated vasculature to improve tumour therapy.Solid tumor therapy: manipulation of the vasculature with TNF.Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
P2860
Q21245599-66AEE89E-BA7B-455C-99E4-4BF88DD13F38Q26748650-1D3D5B32-0F11-4195-B75D-EF5232BE36FAQ28078725-C6753918-1C17-4D65-A946-1B0383379331Q28088685-286BBD0C-D7CE-4A28-A672-13A669CC2D91Q28728301-5350B388-88B4-4C35-8F93-ECBD0C41D12AQ30478546-45B48769-55BF-48E3-A47F-0C045ACCC562Q33177384-4E917F73-ACE6-4A6A-A269-0000513F7A6AQ33178110-4633EBBA-FD7F-4350-A2C3-89B9242DE265Q33178477-51F6C535-1A04-4614-A840-3CFDA0C74453Q33178607-74CB27D4-2769-4A7F-8F94-F542FDDC195EQ33180038-33DC447E-D165-419A-8BE6-80C9D1DC079DQ33180936-F6597260-3330-418B-B4DF-9A4CEA8D7CE6Q33181229-F4F23E21-C689-432A-B9AA-2B9902B1D7EDQ33181472-9DB2AAF8-20E9-41E6-817C-9988B3AE4FECQ33183242-B43145AF-5720-422C-8DAE-3D6A57DAA16FQ33183585-1DB15ABA-0C7E-4D51-A53C-3BA3B5234C68Q33183884-98467319-1E08-4366-AC8D-5113B8163D21Q33186209-E7DDA92E-8CEC-447D-B311-B9108BDF5E82Q33209414-A70C43CD-61CF-440F-A78D-04FA7F1E4E90Q33224018-B83F8766-CAC1-49C7-9E7C-7F92806C93C8Q33263624-DA76C56E-A1EB-4CDB-9621-8AE9BED9581CQ33309291-91D51315-B6BF-47B3-B725-A8D6BDBAE88AQ33325343-8B473BB6-3FF4-49DE-A6B6-4E94D9CD6317Q33339947-FA808E78-E263-47EF-B6C0-E360A4E23D81Q33560777-F357E590-823B-469A-B261-8151945312A9Q33685546-1926A790-5B9C-45D5-91F1-D10D2AE1B657Q33737928-8C18CDDB-F2BC-4DBC-B96A-8CB0FB93CF79Q33880165-A0501B40-81B0-45E6-B284-992EA14D0586Q33955599-0B45636B-0A0E-4AD7-B69A-0D85A9118AB0Q34006197-86493363-E4EF-4E77-A8D0-64BBAE2868F2Q34054797-DE87E10E-D1B2-481A-AC5B-9BBC0119F478Q34340824-650F983F-A155-4F19-85B0-4416E2DCF963Q34419681-CBF61CEC-1EFF-4001-8C24-489A1AF18BD2Q34655297-E4570EB4-665C-4D3F-A189-96029DEE961BQ34662879-9965570A-5224-4DA7-B5ED-DBEF2A6416C1Q34665261-C9A44E04-E642-4985-8065-42CF75EDC70FQ35072789-63E728E6-6350-4083-802A-CD9F682CD504Q35142322-107EAE4E-CCFC-499B-869A-836CA5DF4EF2Q35605468-0680F701-50DF-4118-B2EF-6F2E6AA10F36Q35690539-992F7A68-A7BD-4AC7-9135-68247A9F316D
P2860
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Isolated limb perfusion with t ...... lticenter European experience.
@en
type
label
Isolated limb perfusion with t ...... lticenter European experience.
@en
prefLabel
Isolated limb perfusion with t ...... lticenter European experience.
@en
P2093
P1433
P1476
Isolated limb perfusion with t ...... lticenter European experience.
@en
P2093
Eggermont AM
Hoekstra HJ
Kettelhack C
Klausner JM
Lejeune FJ
P304
756-64; discussion 764-5
P356
10.1097/00000658-199612000-00011
P407
P577
1996-12-01T00:00:00Z